Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease

Trial Profile

Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Citrate/heparin/taurolidine (Primary)
  • Indications Bacterial infections; Catheter infections; Catheter thrombosis; Mycoses
  • Focus Registrational; Therapeutic Use
  • Acronyms LOCK-IT-100
  • Sponsors CorMedix
  • Most Recent Events

    • 26 Oct 2017 According to a CorMedix media release, data from this trial will be discussed at the worlds premier nephrology meeting, the American Society for Nephrologys Kidney Week.
    • 26 Oct 2017 According to a CorMedix media release, the company is planning an interim efficacy analysis of this trial.
    • 09 Aug 2017 According to a CorMedix media release, completion of enrollment is anticipated by 2Q18 and top-line data will be available in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top